Compare OPAL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | GANX |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 72.7M |
| IPO Year | 2021 | 2021 |
| Metric | OPAL | GANX |
|---|---|---|
| Price | $2.42 | $1.76 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.91 | ★ $7.50 |
| AVG Volume (30 Days) | 263.6K | ★ 714.6K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | 31.46 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $348,975,000.00 | $55,180.00 |
| Revenue This Year | $17.60 | N/A |
| Revenue Next Year | $8.78 | N/A |
| P/E Ratio | $16.40 | ★ N/A |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.26 | $1.41 |
| 52 Week High | $4.08 | $4.34 |
| Indicator | OPAL | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 37.17 |
| Support Level | $2.05 | $1.60 |
| Resistance Level | $2.54 | $2.03 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 80.37 | 2.41 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.